Melanotan II vs Pasireotide
Overview
Melanotan II is primarily a cosmetic & skin peptide, while Pasireotide is used for hormonal.
This page compares Melanotan II and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Melanotan II | Pasireotide | |
|---|---|---|
| Category | Cosmetic & Skin | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 250-500 mcg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | as needed | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Skin tanning without UV exposure, increased libido, potential appetite suppression | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Nausea, facial flushing, darkening of moles, potential cardiovascular effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Melanotan II is categorised under Cosmetic & Skin, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Melanotan II: not FDA-approved; compounding permitted with a prescription as of April 2026. Pasireotide: FDA-approved.
Dosing. Melanotan II is typically dosed at 250-500 mcg (as needed). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Melanotan II and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Melanotan II and Pasireotide?
- Melanotan II is primarily a cosmetic & skin peptide, while Pasireotide is used for hormonal. Melanotan II is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Pasireotide is FDA-approved for one or more indications.
- What is Melanotan II used for?
- Tanning, libido.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Melanotan II and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Melanotan II and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Melanotan II or Pasireotide FDA-approved?
- Melanotan II is not FDA-approved; compounding permitted with a prescription (as of April 2026). Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Melanotan II — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references